Rapport Therapeutics (RAPP) Other financing activities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Other financing activities data on file, last reported at $273000.0 in Q1 2026.

• Other financing activities for Q1 2026 came in at $273000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $15.8 million (up 1.79% YoY), and the FY2023 annual result was $134000.0, changed N/A from the prior year.
• Other financing activities grew to $273000.0 in Q1 2026 per RAPP's latest filing, from $63000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $15.5 million in Q2 2024 and troughed at -$29000.0 in Q2 2023.
• A 4-year average of $3.2 million and a median of $87000.0 in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2025: Other financing activities jumped 53548.28% in 2024, then tumbled 99.59% in 2025.
• A 4-year view of Other financing activities shows it stood at -$29000.0 in 2023, then jumped by 53548.28% to $15.5 million in 2024, then plunged by 99.59% to $63000.0 in 2025, then soared by 333.33% to $273000.0 in 2026.
• Business Quant data shows RAPP's Other financing activities at $273000.0 in Q1 2026, $63000.0 in Q2 2025, and $15.5 million in Q2 2024.